CompanyGLPGF LKFTNasdaq, OTC2800 Mechelen

Lakefront Biotherapeutics NV

Lakefront Biotherapeutics develops gamgertamig, a BCMAxCD3 T-cell engager in clinical development for autoimmune diseases.

SEC EDGAR ClinicalTrials.gov lakefrontbio.com

6-KSep 29Latest SEC filing

Sep 29Latest story

September 2026

Lakefront Biotherapeutics reports September 21 to 25 buyback, holdings reach 1,633,594 shares

Sep 29M&ALakefront Biotherapeutics NVUpdated

August 2026

FDA grants orphan drug status to Lakefront's gamgertamig for pemphigus

Aug 25Regulatory milestoneLakefront Biotherapeutics NV

Lakefront reports H1 2026 results after closing Ouro Medicines deal with Gilead

Aug 12Quarterly updateLakefront Biotherapeutics NV

Lakefront Biotherapeutics discloses six weeks of share buybacks through July 31

Aug 4M&ALakefront Biotherapeutics NV

July 2026

Lakefront board member Fontoura resigns after Sanofi names him R&D chief

Jul 13PeopleLakefront Biotherapeutics NV Sanofi